Mithra Pharmaceuticals: MITHRA LAUNCHES ITS PRODUCT TIBELIA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Mithra Pharmaceuticals: MITHRA LAUNCHES ITS PRODUCT TIBELIA ON THE GLOBAL MARKET

                                                                                                                                                         PRESS RELEASE

Mithra launches ITS product Tibelia [1] on the GLOBAL market

  • Mithra Pharmaceuticals received 14 Marketing Authorizations (MA) in 12 European countries for its product based on tibolone.
  • Mithra should receive shortly 3 more authorizations for France, Italy and Greece.
  • Tibelia received 24 months' shelf-life and should be able to extend this to 36 months in 2017, what would give the product a unique advantage on the market and would make it more competitive than its competitors.
  • In 2016, Mithra signed 8 License and Supply Agreements.
  • Mithra expects to sign other agreements with Ukraine, Russia, Chile, Singapore, France and Switzerland.
  • Mithra estimates, according to the sales forecasts of his distributors, incomes in double digit for the next five years.

Liège, Belgium, 22 December 2016 - Mithra Pharmaceuticals, a company focused on Women's Health, announces today that it obtained 14 Marketing Authorizations for the commercialization of its product Tibelia in the United Kingdom, Belgium, Holland, Luxembourg, Spain, Portugal, Germany, Hungary, Poland, Norway, Sweden and Finland. Mithra is still waiting for 3 MA in France, Greece and Italy that should be received by the beginning of 2017.

The product based on tibolone developed by Mithra will be more competitive due to its extended shelf-life.

Valérie Gordenne, CSO Mithra Pharmaceuticals: " At this stage, we believe we can justify a shelf-life of 36 months versus 24 months for the competitors. Currently, data are available on 24 months for the pilot batches. Trends show a possible stability extension. The results are confirmed on the first industrial batch (18 months). The best stability of the active ingredient in the formulation is linked to specific components of this formulation, for which a patent has been applied."

In 2016, Mithra signed 8 License and Supply Agreements in the United Kingdom, Spain, Switzerland, Germany, Benelux, Australia, South Africa, Canada and Finland for a total amount in double digit, down payments included. In 2017, Mithra expects to sign other agreements with Ukraine, Russia, Chile, Singapore and France

In United Kingdom, marketing is already effective, as well as it will be effective in Spain and Holland in January 2017.

François Fornieri CEO Mithra Pharmaceuticals: "Obtaining a Marketing Authorization for a product candidate is a real recognition of the unique expertise of our team in terms of development and regulatory affairs. Tibelia is set to be a competitor on the European market. It is indeed a 'complex' therapeutical solution as tibolone, the active ingredient involved, is known as a particularly unstable active ingredient, presenting many challenges in terms of development. Obtaining marketing authorisations for such a product is a significant validation for Mithra's development and regulatory expertise, which was previously demonstrated in the development of Mithra's first R&D projects developed in the past, and which will continue to serve it well as it continues to develop and prepare the regulatory pathway for its lead products based on Estetrol."

The global market of tibolone is an attractive and growing market of EUR 131 million [2] , accounting for an increase of 4.3% in value [3] . In terms of volume, this market represents 315 million tablets, up 2% [4] . 

About Tibelia

Tibelia is a synthetic steroid (tibolone) intended to be used for hormone replacement therapy. Tibelia is a product that mimics the activity of the female sex hormones in the body, and is used especially for the relief of symptoms occurring after menopause. In some countries, this product is also used for the prevention of osteoporosis. It has been demonstrated that tibolone has favourable effects on various tissues in the body, such as brain, vagina and bone [5] .

Pictures

For pictures of François Fornieri, please click on the following link:

http://www.mithra.com/en/logo/

For more information, please contact:

Press

Julie Dessart Chief Communication Officer +32 4 349 28 22 / +32 475 86 41 75 press@mithra.com

Investor Relations

François Fornieri, CEO +32 4 349 28 22 investorrelations@mithra.com

Consilium Strategic Communications Jonathan Birt, Sue Stuart, Hendrik Thys +44 2 037 095 700 mithra@consilium-comms.com

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart, is a Euronext listed pharmaceutical company (MITRA) focused on Women's Health. Mithra's mission is to improve every stage of women's life with innovative and accessible pharmaceutical solutions. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical solutions in four therapeutic fields of women's health: fertility and contraception, menopause and osteoporosis, gynecological infections and female cancers.

Mithra has an approximate headcount of 141 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com

[1] Code name for the product based on Tibolone developed by Mithra. Every distributor is free to choose the name he wishes to commercialize locally.

[2] Source : IMS Q3/2015

[3] Source : IMS Q3/2015

[4] Source : IMS Q3/2015

[5] Livial ® Patient Information Leaflet.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 160

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 130

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 48

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 63

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 84

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 113

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 98

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Vusion's 2030 Plan Puts Recurring Revenue First At Scale

Updated Category News Views 77

Shelf labels are not exactly romance, yet Vusion has turned them into a serious growth machine. The 2030 plan is not really about hanging more electronic displays in aisles; it is about making those displays, sensors and store connections produce software and service revenue for years. That is the part of this story worth watching. The Hardware Base Is Becoming the Hook...

Continue Reading
CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 92

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading

Top 5 Most Recently Viewed Articles

China's Investment Landscape Transformed by Market Reforms

Updated Category News Views 451

China's Market Value Reforms Enhancing Investment Confidence Recent developments in China’s market management are poised to reshape the landscape of investment, significantly boosting investor confidence. UBS analysts emphasize that these new measures represent a critical shift, aiming to cultivate a healthier environment for both domestic and foreign investors. Key...

Continue Reading
CI Financial Sees Significant Growth with Total Assets of $525B

Updated Category News Views 134

CI Financial Achieves Impressive Total Assets for October CI Financial Corp. (“CI”) (TSX: CIX) has recently announced a remarkable total asset figure of $525.3 billion. This impressive number celebrates a multifaceted asset landscape, including asset management assets totaling $136.1 billion, Canadian wealth management assets of $100.4 billion, Canadian custody assets...

Continue Reading
Carlyle Credit Income Fund Plans Second Quarter Results Update

Updated Category News Views 193

Carlyle Credit Income Fund Plans Second Quarter Results Update The Carlyle Credit Income Fund, often referred to as CCIF, has exciting news. The Fund is set to unveil its financial performance for the second quarter following market close on a specific upcoming Tuesday in May. This announcement represents a crucial moment for stakeholders and potential investors eager to...

Continue Reading
Lithia Motors Boosts Earnings: Price Target Climbs Significantly

Updated Category News Views 75

Lithia Motors Sees Price Target Hike After Strong Earnings Recently, Lithia Motors (NYSE: LAD) garnered attention in the financial markets as Stephens, a prominent financial services company, announced an increase in its price target for the automaker. The target officially rose from $360 to $405. This update follows a robust earnings report for the third quarter,...

Continue Reading
VFC Corporation Achieves 52-Week High: What it Means for Investors

Updated Category News Views 95

VFC Corporation Achieves New Market Heights In a remarkable surge, VFC Corporation's stock has reached a significant milestone by hitting a 52-week high at $20.7. This impressive figure is a clear indication of a substantial turnaround, demonstrating a remarkable 23.84% increase over the last year. Confidence among investors has rebounded as they recognize the apparel...

Continue Reading